Can a Calcium Score Be Reduced? The Scientific Facts

Coronary artery calcium scores almost never go down. Once calcium deposits form in the walls of your heart’s arteries, the body has no reliable mechanism for reabsorbing them, and no medication has been shown in large trials to reverse an established score. What can happen, and what growing evidence supports, is slowing the rate at which that number climbs and changing the character of the calcium in ways that actually lower your risk of a heart attack. The distinction between shrinking a number on a scan and reducing the danger that number represents turns out to be the more important story.

What the Calcium Score Actually Measures

The coronary artery calcium (CAC) score, usually called the Agatston score after the cardiologist who developed it, multiplies the total area of calcium deposits in your coronary arteries by a weighting factor based on how dense those deposits are.¹ A score of zero means no detectable calcium. Scores of 1 to 99 are mild, 100 to 399 moderate, and 400 or above is considered severe. Because the formula weights both area and peak density, your score can rise either because new calcium appears or because existing deposits grow denser. This matters when we talk about whether interventions are “raising” or “lowering” the score, because the clinical meaning of a change depends on what kind of change it is.

The Natural Direction Is Up

Without any intervention, calcium scores climb over time, and the higher your starting score, the faster they tend to rise in absolute terms. In a study of symptomatic patients followed for about 18 months, those starting with scores above 400 added a median of roughly 110 Agatston units per year, while those starting between 1 and 30 added only about 3 units per year.² A separate study of asymptomatic people found a mean annual progression of about 10 Agatston units, with roughly one in five participants gaining more than 10 points per year.³ The trajectory is essentially one-directional. In large population studies, spontaneous decreases that aren’t explained by scan variability are vanishingly rare.

That upward trajectory also carries real prognostic weight. A study of over 4,600 people found that the rate of calcium progression independently predicted death from any cause, even after accounting for the baseline score, age, and traditional risk factors. Those with the fastest progression had roughly three times the mortality risk of those whose scores barely budged.⁴ In the large Multi-Ethnic Study of Atherosclerosis (MESA), people whose scores jumped by 300 or more units per year faced about six times the risk of a hard coronary event compared to those with no progression.⁵ So slowing that climb, even if you can’t reverse it, is a meaningful clinical goal.

The Statin Paradox

If you’ve heard that statins make calcium scores worse, you’ve heard a half-truth that needs context. Statins do tend to increase the Agatston score over time, sometimes faster than if you weren’t taking them at all.⁶ But the reason they do this is the reason they work. Statins shrink the soft, fatty, rupture-prone components of plaque and promote a shift toward denser, more stable calcification.⁷ Think of it as the difference between a volcano with a thin, crumbly crust over a pool of magma versus the same volcano with a thick, solid cap. The solid cap registers as “more calcium” on a scan, but it’s far less likely to blow.

This has important implications for how follow-up scans should be read. A large analysis from the PARADIGM registry found that in people not on statins, a rising calcium score reliably signals that both calcified and non-calcified plaque are growing. In people on statins, a rising score reflects growth of the calcified component only, while the dangerous soft plaque is shrinking or stable.⁸ The same number on the report means something fundamentally different depending on whether you’re taking a statin. Many cardiologists now caution against using serial calcium scoring to monitor statin therapy precisely because the score going up can actually be a sign the drug is doing its job.

Why Calcium Density Changes What the Score Means

The Agatston score treats all calcium as roughly equivalent, but the body treats different kinds of calcium very differently. In the MESA cohort, researchers found that at any given volume of calcium, denser deposits were associated with fewer heart attacks and strokes. Each standard-deviation increase in calcium density was linked to about a 27% lower risk of coronary heart disease and a 29% lower risk of cardiovascular disease overall.⁹ Dense calcium acts like a biological seal over vulnerable plaque, making it less likely to crack open and trigger a clot. This is a key reason why therapies that drive the score up by densifying calcium, like statins, still reduce heart attacks.

Research into how plaque composition relates to outcomes goes further. In a study of asymptomatic people at intermediate risk, the calcium score on its own was not significantly associated with long-term cardiovascular events. What was strongly predictive was the burden of non-calcified and mixed plaque.¹⁰ In other words, the soft stuff is what kills you. Purely calcified plaque, especially when it’s dense, often represents the body’s attempt at stabilization rather than active disease. This doesn’t mean a high calcium score is harmless, because high scores usually correlate with large amounts of all plaque types, but it does mean the score alone doesn’t capture the full risk picture.

What Slows Progression

If you can’t erase calcium, the next best thing is keeping the score from climbing as fast. The MESA study assessed this directly by creating a lifestyle score based on four factors: regular exercise, a healthy diet, not smoking, and maintaining a healthy weight. People who hit all four had annual calcium progression that was about 11 Agatston units per year slower than those who hit none of these benchmarks.¹¹ The relationship was graded, meaning each additional healthy habit added incremental benefit. Over years, those differences compound. The same study found that a healthier lifestyle was also associated with lower all-cause mortality over about 7.6 years of follow-up.

Blood pressure control appears to be another lever, though it has limits. A Korean registry study found that maintaining normal systolic blood pressure over time was associated with significantly slower calcium progression in non-diabetic adults. However, the same protective association was not seen in people with diabetes, suggesting that the metabolic environment of diabetes drives calcification through mechanisms that blood pressure control alone can’t override.¹²

Dietary patterns matter as well. Data from the CARDIA study, which has followed young adults for decades, found that an animal-based low-carbohydrate diet was associated with roughly 46% greater risk of calcium score progression compared to a plant-based low-carbohydrate pattern, which showed no such association.¹³ The distinction suggests it’s not carbohydrate restriction per se that matters but what you replace carbohydrates with. Swapping carbs for red meat and animal fat appears less favorable for your arteries than swapping them for nuts, seeds, and plant oils.

Advanced Lipid-Lowering Therapy

For people already on statins who want to slow calcium progression further, PCSK9 inhibitors show promise. These injectable drugs, which powerfully lower LDL cholesterol beyond what statins achieve alone, were associated with roughly half the annual rate of calcium score progression compared to statin monotherapy. Statin-only patients saw about 30% annual progression in calcium score, while those adding a PCSK9 inhibitor saw about 14%.¹⁴ These drugs didn’t reverse calcium, but they meaningfully slowed the accumulation. Combined with the plaque-stabilizing effects of statins, aggressive LDL lowering appears to be the best pharmacological strategy currently available for managing coronary calcification.

GLP-1 Receptor Agonists and Plaque

The class of medications originally developed for type 2 diabetes and now widely used for weight loss, GLP-1 receptor agonists, is generating cardiovascular data that extends beyond glucose control. In diabetic patients who had already experienced an acute coronary event, GLP-1 receptor agonist treatment was associated with significant regression of plaque burden at one year. The treated group saw plaque burden decrease by about 6%, while the control group stayed essentially flat.¹⁵ A separate study of diabetic patients after stent placement found that GLP-1 receptor agonist use significantly reduced both in-stent restenosis and progression of disease in non-stented arteries.¹⁶

To be clear, these studies measured plaque volume and composition, not the Agatston calcium score specifically. Plaque regression and calcium score reduction aren’t the same thing. But because the dangerous part of plaque is the non-calcified, inflammatory component, shrinking overall plaque volume is arguably more clinically meaningful than any change in the calcium number. The evidence here is still early-stage and mostly in diabetic populations after acute events, so it’s not yet clear how far these benefits extend to the general population.

The Measurement Itself Can Fool You

Before you celebrate or panic over a change in your calcium score between two scans, know that the test has meaningful scan-to-scan variability even when nothing has changed inside your arteries. A study from the MESA cohort found that the average relative difference between back-to-back scans taken on the same day was about 20% for the Agatston score.¹⁷ Breathing patterns, heart rate, the exact position of the patient, and even the brand of CT scanner all affect the result. Using overlapping image slices can reduce this variability to a median of about 9%, but not all imaging centers use this technique.¹⁸

Researchers have tried to define what counts as a “real” change versus noise. One analysis calculated that for someone with a measurable baseline score, the smallest statistically significant change is roughly five times the square root of the starting Agatston value. For someone with a baseline score of 100, that means a change of about 49 points in either direction could be pure measurement artifact.¹⁹ This is a wide margin. Some people who believe their score has dropped after a lifestyle change or supplement regimen may simply be looking at the inherent wobble of the test. If you’re comparing two scans, using the same scanner, the same imaging protocol, and ideally the same imaging center gives you the best shot at a meaningful comparison.

Chelation Therapy and Vitamin K2

Two alternative approaches frequently discussed online deserve scrutiny. EDTA chelation therapy, which involves intravenous infusion of a compound that binds calcium and metals, was examined in a small retrospective pilot study of 10 patients. After an average of about 27 sessions over roughly three years, calcium scores dropped by an average of 27%.²⁰ Ten patients, no control group, and a retrospective design make this about the weakest form of evidence that exists in clinical research. Given the measurement variability described above, some of the observed decrease could be noise. The idea isn’t biologically implausible, but the evidence is nowhere near sufficient to recommend it, and chelation carries its own risks including kidney damage.

Vitamin K2 is another popular supplement claim. The biological rationale is real: vitamin K2 activates a protein called matrix Gla protein, which in its active form inhibits calcification of soft tissues including blood vessels.²¹ Laboratory and animal studies support this mechanism. But having a plausible mechanism is not the same as having clinical proof that K2 supplements reverse established calcium scores in humans. Large-scale trials demonstrating that K2 reduces coronary calcium in people are still lacking. It may prove to be useful for prevention of new calcification, particularly in populations deficient in vitamin K, but the idea that it “dissolves” existing calcium deposits runs ahead of the data.

The Exercise Paradox

Lifelong endurance athletes present a puzzle that underscores why the calcium score can’t be read in isolation. Compared to sedentary controls, lifelong endurance sport participants were about 58% more likely to have calcified coronary plaques.²² At first glance, this seems to contradict everything we know about exercise and heart health. But plaque composition in athletes tends to be dominated by calcium rather than soft, vulnerable components.²³ This parallels what statins do: shift the balance toward stable, dense calcification and away from the inflammatory, rupture-prone material that actually causes heart attacks.

An athlete with a calcium score of 200 and a sedentary smoker with a calcium score of 200 are not in the same cardiovascular situation despite having the same number on a report. The athlete’s plaque is more likely to be stable. The smoker’s plaque is more likely to contain the soft, lipid-rich material that precedes acute events. The score alone cannot make this distinction, which is part of why some cardiologists have moved toward CT angiography for patients whose clinical picture doesn’t match their calcium number.

When Calcium Actually Gets Removed Physically

There is one scenario in which coronary calcium is truly eliminated: during interventional procedures for severely calcified blockages that are already causing symptoms. Rotational atherectomy uses a tiny diamond-tipped burr to shave away calcium inside the artery, while intravascular lithotripsy uses sound waves to crack calcified plaque so a stent can be placed. A large prospective study comparing these approaches in over 1,000 patients found them similarly effective, with procedural success rates around 85-86%.²⁴ These techniques are used to enable stent deployment in arteries so calcified that a stent alone wouldn’t expand properly, not to lower a calcium score for its own sake.²⁵ No one undergoes rotational atherectomy to make a screening number look better.

Two Types of Arterial Calcification

Not all arterial calcification represents atherosclerosis. The calcium picked up on a coronary scan is almost always intimal calcification, meaning it sits within plaque that has formed in the inner lining of the artery. But a separate process called medial calcification occurs in the middle muscular layer of artery walls and resembles bone formation rather than plaque disease. Medial calcification is more strongly associated with diabetes and aging than with the classic cholesterol-driven risk factors like smoking or high LDL.²⁶ Standard CT calcium scoring can’t distinguish between these two types. This is mostly relevant for diabetic patients, who may have higher calcium scores partly because of medial calcification that has different biological implications and likely responds differently to treatment than atherosclerotic calcium does.

Research into therapies that specifically target arterial calcification at the molecular level, such as blocking smooth muscle cell transformation into bone-like cells or boosting natural calcification inhibitors, is active but still preclinical. A challenge researchers face is that many of the molecular pathways involved in arterial calcification overlap with normal bone formation, so drugs that dissolve arterial calcium could simultaneously weaken bones.²⁷ This biological overlap is a major reason we don’t have a pill that simply erases coronary calcium.

How a High Score Affects People Psychologically

Learning you have a high calcium score provokes real anxiety. In the ROBINSCA trial, which randomized thousands of people to different cardiovascular screening strategies, those who received a high CAC result experienced significantly more anxiety after getting their results compared to those who screened low risk or who were assessed by traditional risk factors instead.²⁸ Interestingly, the anxiety bump was statistically real but didn’t cross the threshold considered clinically meaningful. And there’s an upside: seeing calcium in your arteries is a powerful motivator. Systematic reviews have found that visualization of coronary calcium strongly motivates patients to start and stick with preventive medications and lifestyle changes.²⁹ The emotional response is uncomfortable, but it often translates into behavior that reduces risk. If you’ve received a score that scared you, the productive response is channeling that alarm into the modifiable factors where evidence is strongest: lipid management, blood pressure, diet, exercise, and smoking cessation.

What Plaque Composition Tells You That the Score Cannot

As imaging technology advances, there’s a growing sense among researchers that the Agatston score, useful as it is for initial screening, misses critical details. When patients with suspected coronary artery disease were followed using CT angiography, which visualizes plaque composition rather than just calcium, the pattern of progression varied dramatically by baseline calcium level. Those starting with zero calcium who developed plaque accumulated soft, non-calcified material at a ratio of about 5.5 to 1 over calcified plaque. Those starting with scores of 400 or above accumulated calcified plaque at a rate about 16 times that of non-calcified plaque.³⁰ In practical terms, new plaque in someone who already has extensive calcium is predominantly the safer, calcified variety. New plaque in someone starting from zero tends to be the more dangerous kind. The calcium score captures only one layer of a more complex story, and the future of cardiovascular imaging likely involves moving beyond a single number toward a fuller characterization of what’s actually sitting in your arteries.